Carmine N. Stengone

President and Chief Executive OfficeratContineum Therapeutics· In proxies 2023–2025

Pay in FY2025-30% from the year before · Contineum Therapeutics stock -22.0% the same year

Carmine N. Stengone was paid $3.4M in FY2025 (Dec), down 30%. Contineum Therapeutics stock fell 22.0% that year.

Pay$100 in the stock at the end of FY24 → $78

Pay is from the Summary Compensation Table of each Contineum Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

CTNM
Contineum TherapeuticsPublic company · 3 yr
- President and Chief Executive Officer2023 – Present · 3 yrStock in role -41%

Roles come from the proxy statements of each company.

Activity

Pay
Contineum Therapeutics CEO pay fell 30% to $3.4M. The stock fell 22% in FY2025 (Dec).
DEF 14AApr 30, 2026
Pay
Contineum Therapeutics CEO pay rose 112% to $4.9M in FY2024 (Dec).
DEF 14AApr 29, 2025

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?